<DOC>
	<DOC>NCT00537082</DOC>
	<brief_summary>To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)</brief_summary>
	<brief_title>Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Male and female patients aged 1860 Patients with a diagnosis of multiple sclerosis Patients with a history or presence of chronic disease of the immune system other than MS Patients with a history or presence of malignancy, pulmonary or heart disease, etc. Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>FTY720,</keyword>
	<keyword>MS</keyword>
</DOC>